Search Results for "Pharmac Cost Of Sativex In New Zealand"

05:14 EDT 6th July 2015 | BioPortfolio

Matching Channels

Marginal cost

TASH Biotechnology

Shanghai TASH Biotechnology Co.,Ltd. specializes in peptide development on the basis of high technology. TASH Biotechnology are focusing on custom peptide synthesis, and the research, development...

CaptureSelect

BAC’s CaptureSelect products are affinity ligands and affinity resins created by a proprietary technology based on Camelid-derived single domain antibody fragments for the purification of biop...

CombiCult

CombiCult® is an award winning, combinatorial screening technology that allows scientists to discover new and improved stem cell differentiation protocols. How Combicult® works A short o...

Latin America

Latin America encompasses the Caribbean, South America and Central America. These countries are important players in the biotechnology industry, not only as consumers, but as contributors. The env...

Matching News

New Zealand’s PHARMAC calls for information on anti-diabetic agents

New Zealand’s Pharmaceutical Management Agency, PHARMAC, today revealed it is interested in receiving…

PHARMAC in negotiations over rare disorders medicines

New Zealand’s Pharmaceutical Management Agency, PHARMAC, is in active negotiations with several suppliers…

NZ’s PHARMAC to fund Janssen prostate cancer drug

New Zealand’s Pharmaceuticals Management Agency PHARMAC will begin funding for the prostate cancer…

Hemophilia treatments funding proposal for New Zealand

New Zealand’s Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal involving…

Study looks at the burgeoning cost of cancer in New Zealand

The cost of treating cancer in the New Zealand public health sector is more than $800 million annually – hundreds of millions higher than previous estimates, according to University of Otago researc...

Late-stage failure for Otsuka and GW cancer pain drug

Otsuka and GW Pharmaceutical’s multiple sclerosis drug Sativex has failed to meet the primary endpoint in its first Phase III trials in cancer pain. Sativex (nabiximols) is derived from cannabis and...

Zealand Pharma A/S: Zealand gives three presentations at the American TIDES 2015 conference - including as keynote speaker

• Keynote talk on "Peptide therapeutics: Status and future directions" by Dr. Lene Jessen, Head of Pharmacology, Zealand • Zealand scientists present on innovative design of therapeutic peptides C...

GW and Otsuka report Sativex failed to meet primary endpoint in cancer pain

UK-based GW Pharmaceuticals and Japanese drugmaker Otsuka have reported that Sativex (nabiximols) did not meet the primary endpoint in the treatment of pain in patients with advanced cancer who experi...

Matching PubMed Articles

Uptake of new medicines: the Pharmaceutical Management Agency of New Zealand (PHARMAC) in the international context.

Exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New Zealand.

Objective Spending on medicines under the Pharmaceutical Benefits Scheme (PBS) represents the ninth largest expense to the Federal Government. A recent report by the Commission of Audit to the Federal...

Sativex-induced neurobehavioral effects: causal or concausal? A practical advice!

Nabiximols (Sativex) is an oromucosal spray, containing delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD), used as treatment for unresponsive spasticity in multiple sclerosis (MS) patients. Sat...

Erratum to: Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex(®)) for Spasticity in Multiple Sclerosis.

A cost-benefit analysis of pre- and post-lambing anthelmintic treatments to twin-bearing ewes on commercial farms in the southern North Island of New Zealand.

Abstract AIM: To conduct a cost-benefit analysis of the administration of anthelmintics to adult ewes around lambing.

Search Whole site using Google

Loading

Advertisement
 
Advertisement
 
Advertisement Advertisement